| Name | Title | Contact Details |
|---|
JT Executive Protection is a security company that offers a wide variety of services and expertise for your security and protection needs.
COMMSOUND CORP is a Chesapeake, VA-based company in the Business Services sector.
WireScreen is a business intelligence platform based in New York City, established in 2019 as a division of The Wire Digital Inc. The company focuses on open-source intelligence (OSINT) to analyze corporate ownership, supply chains, and business relationships, with a strong emphasis on the Chinese market. WireScreen offers several key services, including corporate relationship mapping to reveal connections between businesses, regulatory exposure analysis to identify compliance risks, and due diligence automation that utilizes AI to streamline investigations. The platform also provides API integration for programmatic access to its intelligence database, catering to the needs of multinational corporations, government agencies, financial institutions, and legal teams. The company is led by a team of 25 professionals, including a Pulitzer Prize-winning journalist and former private equity analysts, supported by engineering talent from top tech companies. WireScreen is backed by Sequoia Capital, highlighting its commitment to delivering narrative-driven insights in complex business environments.
A membership community of people with wealth who are committed to supporting progressive social movements which address crucial needs now, next year and beyond.
Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.